Ruboxistaurin.
Publication
, Journal Article
Taulien, CA; Joy, SV
Published in: Drugs Today (Barc)
September 2006
Ruboxistaurin is a potent and specific inhibitor of the beta isoform of protein kinase C. Overactivation of protein kinase C has been demonstrated in patients with type 2 diabetes, and is postulated to play a major role in the pathogenesis of diabetic microvascular complications, which include diabetic retinopathy, neuropathy and nephropathy. The role of protein kinase C in promoting tissue injury in patients with diabetes, and the pharmacologic and clinical studies illustrating the potential of ruboxistaurin to reduce the burden of diabetic microvascular complications will be discussed in this article.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Drugs Today (Barc)
DOI
ISSN
1699-3993
Publication Date
September 2006
Volume
42
Issue
9
Start / End Page
577 / 585
Location
Spain
Related Subject Headings
- Protein Kinase C
- Pharmacology & Pharmacy
- Maleimides
- Indoles
- Humans
- Enzyme Inhibitors
- Diabetic Retinopathy
- Diabetic Neuropathies
- Diabetic Nephropathies
- Clinical Trials as Topic
Citation
APA
Chicago
ICMJE
MLA
NLM
Taulien, C. A., & Joy, S. V. (2006). Ruboxistaurin. Drugs Today (Barc), 42(9), 577–585. https://doi.org/10.1358/dot.2006.42.9.996566
Taulien, Christina A., and Scott V. Joy. “Ruboxistaurin.” Drugs Today (Barc) 42, no. 9 (September 2006): 577–85. https://doi.org/10.1358/dot.2006.42.9.996566.
Taulien CA, Joy SV. Ruboxistaurin. Drugs Today (Barc). 2006 Sep;42(9):577–85.
Taulien, Christina A., and Scott V. Joy. “Ruboxistaurin.” Drugs Today (Barc), vol. 42, no. 9, Sept. 2006, pp. 577–85. Pubmed, doi:10.1358/dot.2006.42.9.996566.
Taulien CA, Joy SV. Ruboxistaurin. Drugs Today (Barc). 2006 Sep;42(9):577–585.
Published In
Drugs Today (Barc)
DOI
ISSN
1699-3993
Publication Date
September 2006
Volume
42
Issue
9
Start / End Page
577 / 585
Location
Spain
Related Subject Headings
- Protein Kinase C
- Pharmacology & Pharmacy
- Maleimides
- Indoles
- Humans
- Enzyme Inhibitors
- Diabetic Retinopathy
- Diabetic Neuropathies
- Diabetic Nephropathies
- Clinical Trials as Topic